Table 1.
Patient | Sex | Age (years) | BMI (kg/m2) | Follow-up (months) | Histological diagnosis | Malignant/Benign (M/B) | (Neo-adjuvant) radiotherapy | Enneking type resection | Histological margins | Surgical time (hours) | Blood loss (ml) | Henderson | Implant related complications (treatment) | Disease status | MSTS | HOOS-PS | NRS rest | NRS activity |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Primary/Secondary (POB/POS/SIB*) | Complication | DFS/AWD/DOD** | ||||||||||||||||
Metastatic disease at presentation (Met) | Classification | |||||||||||||||||
1 | m | 67.1 | 20.2 | 2.7 | Renal cell carcinoma | M/SIB | y | 2 + 3 | Clear | 6 | 9000 | DOD | na | na | na | na | ||
2 | f | 40.5 | 19.3 | 78.1 | Osteosarcoma | M/POB | n | 1 + 2 | Clear | 2.5 | 1500 | DFS | 87% | 80% | 0 | 0 | ||
3 | m | 72.2 | 25.4 | 34.4 | Chondrosarcoma | M/POB | n | 2 | Clear | 4.5 | 2000 | DOD | na | na | na | na | ||
4 | m | 71.8 | 26.6 | 36.3 | Renal cell carcinoma | M/SIB | n | 1 + 2 | Clear | 4.5 | 6000 | DFS | 57% | 80% | 0 | 1 | ||
5 | m | 20.6 | 17.0 | 59.7 | Ewing sarcoma | M/POB | y | 1 + 2 | Clear | 8 | 10,000 | DFS | 83% | 91% | 0 | 0 | ||
6 | m | 52.1 | 33.3 | 34.7 | Renal cell carcinoma | M/SIB | n | 2 + 3 | Clear | 8.5 | 7000 | 3a. 4a | - Loose pubic screws (replacement) -chronic infection (supressive antibiotics) |
DFS | 27% | 44% | 5 | 2 |
7 | m | 29.0 | 27.3 | 33.8 | Chondrosarcoma | M/POB | n | 2 + 3 | Clear | 8.5 | 10,000 | 1a | -Hip dislocation (open reduction) | DFS | 63% | 77% | 0 | 3 |
8 | f | 31.0 | 21.2 | 23.9 | Breast carcinoma | M/SIB/Met | y | 1 + 2 + 3 | Positive | 5.5 | 6500 | 3a. 3a | -Prominent flange (trimming) -Srew S1 radiculopathy (replacement) |
DOD | na | na | na | na |
9 | f | 23.7 | 19.5 | 25.5 | Neurofibroma | B/POS | n | 2 | Clear | 3.5 | 1400 | DFS | 87% | 80% | 0 | 0 | ||
10 | f | 31.1 | 17.8 | 24.4 | Osteosarcoma | M/POB | n | 1 + 2 + 3 | Clear | 4.5 | 2400 | DFS | 47% | 70% | 0 | 2 | ||
11 | m | 40.2 | 20.7 | 17.0 | Chondrosarcoma | M/POB | n | 1 + 2 + 3 | Clear | 5.5 | 4000 | 5b | -Tumour recurrence (hindquarter amputation) | DOD | na | na | na | na |
12 | m | 33.9 | 26.1 | 30.4 | Testicular carcinoma | M/SIB | n | 1 + 2 | Clear | 6 | 2000 | DFS | 63% | 73% | 5 | 7 | ||
13 | m | 38.0 | 30.7 | 27.3 | Giant cell tumour of bone | B/POB | n | 2 | Clear | 5 | na | DFS | 43% | 66% | 3 | 7 | ||
14 | f | 22.6 | 18.6 | 45.7 | Ewing sarcoma | M/POB | n | 1 + 2 | Clear | 3 | 1400 | DFS | 63% | 58% | 0 | 5 | ||
15 | f | 16.0 | 18.6 | 44.0 | Osteosarcoma | M/POB | n | 2 | Clear | 4.5 | na | DFS | 67% | 70% | 0 | 3 | ||
Median | 33.9 | 20.7 | 33.8 | 5.5 | 5000 | 63% | 77% | 0 | 2 |
POB, primary of bone; POS, primary of soft tissue; SIB, secondary in bone.
DFS, disease free survival; AWD, alive with disease; DOD, died of disease.